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Leptin receptor is elevated in carotid plaques from
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Background: Carotid artery lesions from symptomatic patients are characterized by inflammation and neovascularization.
The adipokine leptin promotes angiogenesis and activates inflammatory cells, and the leptin receptor (ob gene-encoded
receptor), ObR, is expressed in advanced atherosclerotic lesions. The present study quantitatively analyzed ObR
messenger RNA (mRNA) expression and immunoreactivity in carotid artery plaques from symptomatic and asymptom-
atic persons. Plaque angiogenesis, gene expression of vascular endothelial growth factor (VEGF), and macrophage
density were also analyzed.
Methods: Carotid endarterectomy specimens were collected from 26 patients undergoing surgery for hemispheric
cerebrovascular symptoms (n  13) or progressive asymptomatic internal carotid stenosis (n  13). A representative
sample, including part of the most active site, was collected from each lesion and evaluated by real-time polymerase chain
reaction analysis for ObRlong and ObRcommon isoforms, VEGF165, and macrophage adhesion molecule-1 (Mac-1) mRNA,
and by immunohistochemistry for ObR, von Willebrand factor (vWF), and CD68 antigen expression.
Results: All plaques exhibited advanced atherosclerosis (American Heart Association class IV through VI). Transcript
levels were preferentially elevated in symptomatic plaques for ObRlong (P  .0006) and ObRcommon (P  .033), with a
simultaneous upregulation of VEGF165 (P  .001) and Mac-1 mRNA expression (P  .003). Immunohistochemical
analysis confirmed a significant increase of ObR antigen levels (P  .011) and CD68-positive inflammatory cells (P 
.049) in symptomatic plaques, whereas neovascularization, evident in all plaques, was similar in both groups (P  .7).
Conclusion: The ObRlong and ObRcommon genes are upregulated and their protein preferentially synthesized in clinically
symptomatic carotid plaques. Moreover, ObR expression is positively correlated with augmentation of gene transcripts
related to macrophage density and neovascularization. These data suggest that ObRlong and ObRcommon may be linked
with histologic features of carotid plaque instability, which are associated with cerebral ischemic symptoms. (J Vasc Surg
2008;48:1146-55.)Vulnerable plaques affecting the cervical carotid artery
frequently undergo rupture, leading to cerebral embolic
events that present clinically as hemispheric transient ische-
mic attacks (TIAs) or ischemic stroke.1,2 Rupture-prone
atherosclerotic plaques typically harbor a sizable necrotic
core close to the lumen, with a thin fibrous cap separating
the core material from the blood stream.3,4 In addition,
clinically symptomatic carotid occlusive disease has been
associated with angiogenesis and macrophage infiltrates
characteristic of complex, unstable plaques.5,6
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1146Leptin, the product of the ob gene, is primarily synthe-
sized by adipocytes, and its plasma levels correlate with
adipose tissue mass.7 This hormone is involved in multiple
pathophysiologic processes linking obesity, insulin resis-
tance, inflammation, hematopoiesis, and angiogenesis.8 In
fact, clinical studies identified leptin as an independent risk
factor for coronary heart disease.9,10 Its systemic levels
correlate with those of C-reactive protein (CRP) and may
be useful in predicting future coronary events.11 Moreover,
hyperleptinemia has been associated with in-stent resteno-
sis after percutaneous transluminal coronary angioplasty,
suggesting involvement of the hormone in the remodeling
process.12 Finally, plasma leptin levels correlate with in-
creased carotid intima-media thickness, an independent
predictor of cerebrovascular occlusive disease and future
stroke,13 implying linkage with atherogenesis.14
Leptin is assumed to exert its effects on the cardiovas-
cular system through interaction with the leptin receptor
(ObR) expressed on the surface of hematopoietic and vas-
cular cells.15 Tissue-specific availability of ObR may there-
fore have a significant effect on leptin-mediated processes.
Atherosclerotic plaques, and especially advanced carotid
lesions, demonstrate abundance of ObR antigen. In fact,
ObR immunoreactivity has been identified in macro-
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smooth muscle cells (SMCs).16,17 Although clinical and
experimental studies have implicated ObR in atherogene-
sis, to our knowledge, no quantitative data on its expression
in human atherosclerotic lesions have been reported so far,
and its potential role in plaque progression and instability
has not been explored. In the present study, we tested the
hypothesis that increased ObR gene expression correlates
with clinical and histologic features of plaque vulnerability.
METHODS
Study population. Atherosclerotic plaques were col-
lected from 26 consecutive patients undergoing carotid
endarterectomy for extracranial high-grade internal carotid
artery (ICA) stenosis (70% luminal narrowing for symp-
tomatic patients). The study included surgical specimens
from 13 symptomatic patients (defined according to the
North American Symptomatic Carotid Endarterectomy
Trial [NASCET] classification)18 presenting with cerebro-
vascular TIAs (n  10) or stroke (n  3) within the last 3
months. All other specimens were collected from 13 clini-
cally asymptomatic patients exhibiting progressive ipsilat-
eral ICA stenosis of80% on serial Doppler examinations.
Normal carotid arteries (n  3) were obtained from organ
donors and served as controls for polymerase chain reaction
(PCR) analyses.
The degree of ICA stenosis was established in two
consecutive Doppler examinations before surgery in all
cases. It was additionally confirmed by computed tomog-
raphy angiography (CTA) in 15 cases, including 12 patients
initially evaluated at the department of neurology, and
three for whomCTA was used to verify the accurate degree
of ICA stenosis, to resolve ambiguous duplex results.
All patients were evaluated neurologically before and
after surgery by a senior neurologist and by amember of the
surgical team. Three patients with a history or clinical
symptoms of stroke underwent a brain CT scan and were
operated on 1 to 3 months after the cerebrovascular
event. Ten symptomatic patients presenting with TIAs
underwent surgery 4 weeks. The study was approved by
the local ethics committee, and written informed consent
was obtained from all patients.
Tissue collection. All plaques were assessed macro-
scopically for signs of luminal ulceration, intraplaque hem-
orrhage, and the presence of a soft or ruptured necrotic
core. After the plaques were washed in normal saline solu-
tion, a representative segment was sampled from each
specimen and immediately snap-frozen for future RNA
analysis. Each of those representative samples included an
8- to 10-mm-long proximal plaque segment that extended
from the bifurcation into the ICA. The remaining speci-
men, including at least 2 to 4 mm of the proximal ICA
plaque, was rapidly fixed in 4% formalin for 8 to 12 hours
and then embedded in paraffin blocks. Great care was taken
to prevent plaque disintegration during division of the
unfixed specimens. All samples contained part of the most
active site of the plaque, identified macroscopically as dis-playing the most advanced atherosclerotic process, fre-
quently including part of the necrotic core.
RNA and complimentary DNA preparation. Plaque
samples, kept frozen in liquid nitrogen, were pulverized by
crushing over dry ice, followed by homogenization (Polytron
PT-2100) in TRIZOL solution (Invitrogen, Carlsbad, Calif)
andRNApreparation.RNAconcentrationwas determinedby
spectrophotometry. Complimentary DNA (cDNA) was syn-
thesized using random hexamer (Promega, Southampton,
United Kingdom) with SUPERSCRIPT II RNase H-
negative reverse transcriptase (Gibco BRL, Paisley, United
Kingdom). The cDNA prepared from the total RNA was
used in real-time PCR analysis for ObRlong, ObRcommon,
VEGF165, and macrophage antigen complex-1 (Mac-1)
mRNA.
Quantitative real-time PCR. Quantitative real-time
PCR was performed on cDNA prepared from total RNA
isolated from vascular samples. Preordered assay-on-
demand kits (Applied Biosystems, Foster City, Calif) were
used according to the manufacturer’s protocol, using the
ABI PRISM 7900HT Sequence Detection System (Ap-
plied Biosystems). Different assay kits were used for each
detected gene: leptin receptor variant 1 (LEP-R orObRlong;
catalog number: HS00174492), leptin receptorcommon
(HS00174497), Mac-1 (HS00167304), and VEGF165
(HS009000057). A Universal PCR Master Mix (Applied
Biosystems) was used. Values were normalized to the ref-
erence gene Abl (Abelson). Samples from normal donor
carotid arteries were used to establish the baseline for each
gene. Those were used as the internal controls to which all
samples obtained from symptomatic and asymptomatic pa-
tients were compared, as well as to the external reference
gene Abl.
Normalization of the results could be obtained by
comparative Ct (Ct) analysis, which gave the arbitrary
score of 1.0 to the control. Comparing patients’ samples
with this value resulted in fold-increase or fold-decrease of
the expression of each detected gene in each sample. The
nominal values for each gene in the control samples, includ-
ing the Abl, represented the actual transcript quantity, and
were always in the range of 10,000 copies  10% (about
cycle 25.5).
The fluorescent probe used was 5=-Fam-CTGGC-
CCAACGATGGCGA-BHQ-3=. The primers used were
forward 5=-TGGAGATAACACTCTAAGCATAACTAA
AGG-3= and reverse 5=-GATGTAGTTGCTTGGGAC-
CCA-3=. Results were analyzed using the SDS 2.1 (Applied
Biosystems) and Excel (Microsoft Corp, Redmond, Wash)
computer programs.
Histology. All plaques were examined histologically
after hematoxylin and eosin and Movat’s pentachrome
staining and then classified according to the AHA criteria,
as defined by Stary and modified by Virmani.3,19 The
classification of advanced class IV through VI lesions relies
primarily on the status of the fibrous cap according to the
size and proximity of the necrotic core to the luminal
surface. These criteria reliably reflect the potential of the
plaque to progress and generate major vascular complica-
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intraplaque hemorrhage, was visualized using Perl’s iron
stain.
Immunohistochemistry. Immunohistochemical analy-
ses were performed on 5-m-thick slides prepared from
paraffin blocks. All plaque specimens (except one asymp-
tomatic) were examined by immunohistochemistry for the
presence of von Willebrand factor (vWF), ObR, and CD68
antigen.
For visualization of intraplaque microvessels, a poly-
clonal rabbit antihuman vWF antibody (DakoCytomation,
Hanburg, Germany) was used, 1:50 diluted in buffer con-
taining background-reducing components (Dako). Fluo-
rescein isothiocyanate (FITC)-conjugated goat antirabbit
immunoglobulin (Ig) G (1:50 dilution; Zytomed, Berlin,
Germany) was used as secondary antibody. Nuclei were
visualized by fluorescence using 4’,6-diamidino-2-
phenylindole (DAPI) counterstaining (Vectashield; Vector
Laboratories, Burlingame, Calif).
Detection of the leptin receptor antigen was performed
as described previously.17 According to the manufacturer’s
specifications, the antibody recognizes both the long and
common isoforms of the leptin receptor. Macrophages
were detected using a mouse monoclonal anti-human
CD68 antibody (dilution 1:100; Dako), followed by a
biotinylated goat antimouse secondary antibody (dilution
1:200; Zytomed) and amino-ethyl-carbazole (Zytomed) as
color substrate. Sections were briefly counterstained with
Gill’s hematoxylin (Thermo Shandon, Pittsburgh, Penn)
andmounted in VectaMount (Vector) before inspection by
Olympus BX51 microscope (Olympus, Mellville, NY).
Quantitative analysis of lesion neovascularization,
macrophage density, and ObR immunoreactivity.
Blood vessels were identified by the presence of circular
structures lined with cells staining positive for vWF and
corresponding cell nuclei demonstrated by DAPI counter-
staining. Two independent investigators, blinded to the
origin of the plaque, graded the presence of blood vessels
by viewing five sections per patient and at least 10 different
fields per slide (1000 original magnification). The follow-
ing scoring systemwas used: 0, no blood vessels; 1, less than
two blood vessels per microscopic field in 50% of micro-
scopic fields; 2, more than two blood vessels per micro-
scopic field in50% ofmicroscopic fields; 3, more than two
blood vessel per microscopic field in at 50% of micro-
scopic fields.
ObR andCD68 immunoreactivity was assessed in three
randomly chosen microscope fields (100 original magni-
fication) per tissue section per patient and quantified by
measuring the immunopositive area and the number of
immunopositive signals using Image-Pro Plus 4.1 software.
(Media Cybernetics, Silver Spring, Md).
Determination of plasma parameters. Plasma sam-
ples were collected from all patients 2 hours before carotid
surgery and stored at –70°C. Samples were assayed for the
biomarkers leptin, soluble leptin receptor, CRP, and inter-
leukin (IL)-6.Leptin was determined using radioimmunoassay kits
(Human Leptin RIA kit, Linco Research Inc, St Charles,
Mo). The sensitivity of the leptin assay was 0.5 g/L, and
the interassay coefficient of variation was 3% to 6%. Human
soluble leptin receptor was determined using solid-phase
enzyme linked immunosorbent assay (Quantikine, Human
Leptin Soluble Receptor kit, R & D Systems, Minneapolis,
Minn). The sensitivity of the assay was 0.06 g/L, the
interassay coefficient of variation was 5% to 9%, and the
manufacturer’s normal range was 13.1-55.4 g/L. CRP
was determined by a standard immunological assay, using
Olympus autoanalyzer (AU 2700, with a normal value of
3 mg/L). IL-6 was measured by chemiluminescent im-
munometric method (Immulite, Diagnostic Products
Corp, Los Angeles, Calif). The sensitivity of the assay was 2
pg/mL, and the interassay coefficient of variation was 5% to
10%. Expected values for healthy individuals are 5.9
pg/mL, at the 95th percentile, as specified by the manu-
facturer.
Statistical analysis. For statistical analysis of differ-
ences in mRNA transcript levels, for ObRlong, ObRcommon,
VEGF165, and Mac-1, nonparametric statistical methods
were used to compare plaque samples from symptomatic
and asymptomatic patients due to the small sample size.
Mann-Whitney test or Wilcoxon rank test for unpaired
population were applied. To correlate transcript levels for
ObR long with VEGF 165, and Mac-1, the Pearson coeffi-
cient method was used. For the comparative assessment of
angiogenesis in symptomatic and asymptomatic specimens,
the Wilcoxon rank test was used. ObR- and CD68-
immunopositive signals were compared using the t test for
unpaired means. To assess differences in categoric variables
(eg, clinical variables in Tables I and II), the Fisher exact
test was used. SAS 9.1 software (SAS Institute, Inc, NC)
was used for all statistical analysis. All tests applied were
two-tailed, and a value of P  .05 was considered statisti-
cally significant.
RESULTS
Baseline demographics and clinical risk factors, includ-
ing diabetes mellitus, dyslipidemia, prevalence of arterial
hypertension, and elevated body mass index (25 kg/m2)
were similar in both patient groups (Table I). Although
cigarette smoking appeared to be more frequent among
symptomatic patients (7 of 13 vs 3 of 13), the difference
was not statistically significant. Histopathologic analysis of
all specimens revealed advanced or complicated atheroscle-
rotic lesions (ie, types IV through VI) in a similar propor-
tion of symptomatic and asymptomatic patients (Table II).
Leptin receptor gene expression and immuno-
reactivity. A significant elevation in the meanObRlong and
ObRcommon mRNA expression was found in plaques from
symptomatic compared with asymptomatic patients (90.6 
25.8 vs 5.12  1.9 arbitrary units [AU], respectively; P 
.0006; Fig 1, column 1). Similarly, analysis of mRNA ex-
pression of the ObRcommon isoform revealed significant
differences between the two groups (84.49 31 vs 56.9
32 AU; P .033; Fig 1, column 2). Immunohistochemical
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munopositive area in symptomatic compared with asymp-
tomatic lesions (1098  143  103/m2 vs 591  109 
103/m2; P  .011). Representative findings are shown in
Fig 2, A-D. In agreement with these findings, a significant
increase was observed in the number of ObR immunosig-
nals per microscope field (540  93.7 vs 873  111; P 
.033).
VEGF and Mac-1 mRNA expression, neovascular-
ization and macrophage density. We analyzed the sam-
Table I. Patient clinical characteristics
Variable Symptomatic Asymptomatic Pa
Patients, No. 13 13 NS
Age, mean  SEM, years 65.5  9.6 67.8  8.2 NS
Sex NS
Male 10 8
Female 3 5
TIA, No. (%) 10 (76.9) 0 .001
Stroke, No. (%) 3 (23.1) 0 NS
BMI, mean  SEM, kg/m2 27.1  2.8 28.5  3.4 NS
Diabetes mellitus, No. (%) 2 (15.4) 4 (30.8) NS
Arterial hypertension,
No. (%) 10 (76.9) 13 (100) NS
Smoking, No. (%) 7 (53.8) 3 (23.1) NS
Dyslipidemia, No. (%) 6 (46.2) 4 (30.8) NS
Ischemic heart disease,
No. (%) 7 (53.8) 8 (61.5) NS
Medications, No. (%)
Statins 7 (53.8) 8 (61.5) NS
Aspirin 12 12
Clopidogrel 3 1 NS
ACE inhibitors 6 (46.2) 3 (23.1) NS
ACE, Angiotensin-converting enzyme; BMI, body mass index; NS, not
significant; SEM, standard error of the mean; TIA, transient ischemic attack.
aNo significant differences were found between patients in the two groups,
as determined by the Fisher exact test.
Table II. Carotid artery plaque characteristicsa
Variable Symptomatic, No. Asymptomatic, No.
Patients 13 13
AHA lesions
Type I and II 0 0
Type III 0 0
Type IV 1 3
Type V and VI 12 10
Intraplaque iron 8 10
Intraplaque hemorrhage 9 8
Overt plaque rupture 3 3
Fibrosis 1 5
Necrotic core 13 10
Intraluminal thrombus 2 2
AHA, American Heart Association.
aFeatures of plaque morphology were generally similar in lesions from
clinically symptomatic and asymptomatic patients. However, minor varia-
tions existed, including excessive fibrosis and extracellular matrix deposition
in asymptomatic specimens. The presence of a necrotic core, overt rupture,
intraplaque hemorrhage, intraplaque iron, and intraluminal thrombosis
were similarly prevalent in the two groups. By the Fisher exact test, compar-
isons between groups were not statistically significant.ples by real-time PCR for VEGF165 transcript as an indica-tor of active angiogenesis. Mac-1 mRNA expression was
also measured as a marker of macrophage density. Both
analyses demonstrated a highly significant increase in
mRNA levels in the symptomatic plaques. Mean VEGF165
transcript levels were 586.2  166 AU in symptomatic
patients vs 36.4  11 AU in asymptomatic patients (P 
.001; Fig 1, column 3), andmeanMac-1mRNAwas 330.8
80 AU in symptomatic vs 20.5  8 AU in asymptomatic
patients (P  .003; Fig 1, column 4). High correlation was
found between ObRlong and VEGF165 mRNA (r  0.98,
P .0001), and withMac-1mRNA (r 0.86, P .0001),
respectively.
Morphologic analysis revealed abundant neovascular-
ization in plaques from either symptomatic or asymptom-
atic patients (Fig 3). Differences in plaque vascularization at
the histologic level were assessed by two independent in-
Fig 1. A,Differences in the level of ObRlong, ObRcommon, vascular
endothelial growth factor 165 (VEGF165), and macrophage anti-
gen complex-1 (Mac-1) messenger RNA (mRNA) expression be-
tween symptomatic (S, black bars) and asymptomatic (AS, gray
bars) plaques were examined using real-time polymerase chain
reaction analysis. For each gene, the mean transcript level 
standard error is presented at the top of the bar. Values are
expressed in arbitrary units. B, Correlation graphs between
ObRlong and VEGF165 messenger mRNAs, and between ObRlong
and Mac-1 mRNAs.vestigators, blinded to the plaque origin. Both examiners’
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of specimen scores differed by one grade level. When
observers’ grading differed, the average grade was used as
the quantitative estimate of the presence of blood vessels in
the specimens. Although symptomatic specimens scored a
slightly higher average neovascular blood vessel count (1.7
vs 1.5), the differences were insignificant (P .7). Neovas-
cularization was located primarily in the subintima, inter-
Fig 2. Immunohistochemical detection of the leptin r
Expression of the leptin receptor was analyzed on par
bifurcation. Representative examples of findings in lesion
asymptomatic are shown. Arrows point to ObR-positive
signal intensity of ObR-positive cells lining the luminal b
vessel (compare B and D). Scale bars, 25 m. E, Quant
with the standard error (error bars). The statistical sign
indicated in the graph.facing the necrotic core, and at the shoulder area. Therewere also vessels within the necrotic core and in the adven-
titia (not shown).
To test for differences in the presence of intraplaque
inflammatory cells, we assessed the number of CD68-
positive cells (Fig 4). Inflammatory cells were most fre-
quently found surrounding cholesterol clefts (Fig 4, B) or
intralesional microvessels (not shown). We found a signif-
icantly increased CD68-immunopositive area in symptom-
or in symptomatic and asymptomatic carotid plaques.
sections through atherosclerotic lesions at the carotid
(A and B) 13 symptomatic patients and (C andD) 12
(red-brown signal). Inserts highlight differences in the
(compare A and C) or within the medial portion of the
e analysis of the ObR-immunopositive area is presented
ce after comparison of both groups using the t test isecept
affin
s from
cells
order
itativ
ificanatic vs asymptomatic lesions (1080  348  103/m2 vs
e tw
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representative findings shown in Fig 4,A-D, and the quan-
titative analysis in Fig 4, E.
Plasma levels of soluble leptin receptor, leptin,
CRP, and IL-6. Mean levels of soluble leptin receptor,
and of leptin, CRP, and IL-6 assessed in plasma samples
from symptomatic and asymptomatic patients revealed no
significant differences for any of the variables (Table III).
Plasma levels of soluble leptin receptor were within the
Fig 3. Immunofluoresence analysis for von Willebran
plaques. The presence of blood vessels is demonstrated i
(A) one representative symptomatic patient and (B) o
exemplary blood vessels. Each specimen was stained u
counterstained with 4’,6-diamidino-2-phenylindole (DA
present in specimens from both patient groups. C,Quan
asymptomatic plaques is presented with the standard err
revealed no statistically significant differences between thnormal range. Mean CRP plasma levels were moderatelyand equally elevated above the normal range in both
groups, andmean IL-6 levels were within the normal range.
These results suggest that over-synthesis of ObR, demon-
strated locally in symptomatic carotid plaques, did not
correlate with systemic plasma levels of leptin soluble recep-
tor as assessed in those patients.
DISCUSSION
The current study tested the hypothesis that ObR ex-
tor (vWF) in symptomatic and asymptomatic carotid
e different microscopic fields of carotid specimens from
epresentative asymptomatic patient. The arrows show
fluorescein isothiocyanate-labeled vWF antibodies and
Scale bars, 50 m. Note that multiple blood vessels are
e analysis of blood vessels comparing symptomatic with
rror bars). The Wilcoxon rank test used for this analysis
o groups.d fac
n thre
ne r
sing
PI).
titativ
or (epression is more prevalent in carotid plaques from clinically
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logic features of unstable atherosclerotic plaques.We found
that ObRlong and ObRcommon isoforms were significantly
upregulated in symptomatic carotid plaques, correlating
with a simultaneous upregulation of VEGF165 and Mac-1
mRNA levels. Moreover, symptomatic lesions contained
significantly higher amounts of ObR protein and CD68-
positive macrophages, suggesting a link between ObR ex-
Fig 4. Immunohistochemical detection of macrophage
CD68-immunopositive macrophages in paraffin section
Representative findings in lesions from (A andB) 13 sym
shown. Arrows point at CD68 antigen-positive cells (red
the CD68-immunopositive area is presented with the
comparison of both groups using the t test is indicated.pression and features of plaque inflammatory components.In corroboration with previous reports,2,20 histopathologic
analysis of specimens from symptomatic and asymptomatic
patients revealed similar proportions of advanced or com-
plicated atherosclerotic lesions. Our findings suggest that
modulation of ObR gene expression is related to specific
circumstances selectively affecting symptomatic plaques.
Quantitative analysis demonstrated that ObR was sig-
nificantly more abundant in symptomatic atherosclerotic
mptomatic and asymptomatic plaques. The presence of
ugh atherosclerotic carotid artery lesions was analyzed.
atic patients and (C andD) 12 asymptomatic patients are
n signal). Scale bars, 25 m. E, Quantitative analysis of
ard error (error bars). The statistical significance afters in sy
s thro
ptom
-brow
standplaques, both at the mRNA and the protein level available
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been shown to take place on vascular and hematopoietic
cells, promoting endothelial cell21 and SMCproliferation22
and activation of inflammatory cells,15 all crucial events in
the pathogenesis of vascular lesion formation.
Plaque neovascularization may be attributed, at least in
part, to the angiogenic properties of leptin,21,23 based on
the colocalization of ObR, VEGF, and neovessels within
atherosclerotic lesions.16 Increased plaque vascularity may
contribute to lesion progression, being a source of nutri-
ents, inflammatory cell recruitment, and intraplaque hem-
orrhage known to destabilize the plaque physically.24
Contrary to previous studies that demonstrated in-
creased proliferation of immature microvessels in carotid
plaques from symptomatic patients,6 our analysis did not
reveal significant differences between symptomatic and
asymptomatic plaques, as assessed by vWF staining for
angiogenesis. This discrepancy may be partially accounted
for by the fact that all our specimens were of advanced or
complex atherosclerosis in which the angiogenic stimuli
may have already generated a full response in microvessel
proliferation. On the other hand, VEGF-A overexpression
in atherosclerotic plaques may contribute to plaque pro-
gression by increasing monocyte adhesion rather than by
increasing neovessel formation.25
Inflammatory infiltrates, composed of macrophages
and T lymphocytes, are typical of advanced atherosclerotic
lesions and characteristically more prominent in unstable
plaques. Apart from their role in the immune response
mechanisms, inflammatory cells synthesize proteases that
may contribute to proteolytic breakdown of fibrous cap
collagen, promoting plaque rupture.26 Symptomatic
plaques exhibit three times more macrophages infiltrating
the fibrous cap compared with asymptomatic plaques.27
Our CD68 immunohistochemistry analysis also demon-
strated a significantly higher degree of macrophage infiltra-
tion in symptomatic carotid plaques, located predominantly at
the shoulder area of the necrotic core, surrounding cholesterol
Table III. Plasma levels of soluble leptin receptor, leptin,
C-reactive protein, and interleukin 6: Comparison
between symptomatic and asymptomatic patients
Factor Symptomatica Asymptomatica
Soluble leptin receptor, /L 28.40  7.08 28.58  3.32
Patients, No.b 16 15
Leptin, /L 11.70  10.22 13.33  9.28
Patients, No.b 25 21
C-reactive protein, mg/L 4.33  6.40 4.88  4.74
Patients, No.b 16 12
Interleukin-6, pg/mL 5.41  0.95 7.00  2.21
Patients, No. 11 9
aNo significant differences were found when comparing symptomatic and
asymptomatic plasma samples, regarding the four biomarkers.
bAdditional samples from similar patients undergoing carotid endarterec-
tomy were examined for these biomarkers, and the results included in the
analysis. The mean value for soluble leptin receptor in 3 healthy volunteer
controls was 30.1 g/L.clefts and angiogenic microvessels.Recent clinical studies demonstrated abundant mature
ObR protein in advanced atherosclerotic lesions.16,17 Ele-
vated levels of ObR protein observed in symptomatic
plaques could be due to increased density of cells that
normally express the receptor. No statistically valid corre-
lation was demonstrated between CD68 and ObR signal
quantitation (data not shown), and unfortunately, we
could not colocalize both antigens because fixation condi-
tions would not allow costaining. Therefore, our findings
suggest that increasedmacrophage density could not be the
sole source of the elevated ObR. As demonstrated in Fig 2
and in a recent publication,17 ObR antigen is present in
both endothelial cells and SMCs, in addition to macro-
phages, in advanced carotid plaques. Regardless of the
origin of ObR, it seems reasonable to assume that local
availability and direct contact between leptin and its recep-
tor may play a role in plaque progression.
Limitations of clinical and imaging (duplex, magnetic
resonance imaging) criteria as guides to decisions in carotid
disease lend importance to the search for diagnostic modal-
ities and biomarkers of the vulnerable carotid plaque.28,29
Such biomarkers are expected to reflect a systemic inflam-
matory state. This is based on the observation that multiple
vulnerable plaques frequently coincide, thereby underlying
the current concept of “the vulnerable patient.”30 In accor-
dance with previous clinical reports,31 however, we found
that neither plasma CRP or IL-6 nor plasma leptin or
soluble leptin receptor levels indicated a state of systemic
vulnerability in clinically symptomatic carotid patients.
Overexpression of ObR in the plaque may therefore repre-
sent a local indicator of elevated risk, independent of sys-
temic plasma biomarkers.
Experimental data in mice have shown that recombi-
nant leptin promotes arterial thrombosis32 and atheroscle-
rosis progression.33 Exogenous leptin administration ag-
gravated the response to experimental vascular injury and
resulted in enhanced neointimal formation and lumen nar-
rowing.22 However, no such effect has been recorded in
vessels from leptin receptor-deficient mice. Furthermore, it
has been demonstrated that defective leptin/leptin recep-
tor pathway signaling protects mice from atherosclerosis
through regulation of the immune response.34 Collec-
tively, these data imply that although leptin is readily avail-
able systemically, its thrombogenic and proatherogenic
properties can be expressed in vivo only in the presence of
intact leptin receptor at the target organ. Furthermore, we
have performed preliminary analyses of leptin protein in a
new series of carotid plaques that reveal substantial antigen
levels in the range of 0.1- to 2.0-ng/mg protein for speci-
mens from both symptomatic and asymptomatic patients
(unpublished data). These results corroborate available
data regarding leptin protein in coronary artery advanced
atherosclerotic plaques,35 thus supporting the assumption
that leptin is involved in carotid atherogenesis.
CONCLUSIONS
We have demonstrated that ObRlong and ObRcommon
transcripts are significantly upregulated in carotid plaques
JOURNAL OF VASCULAR SURGERY
November 20081154 Schneiderman et alof symptomatic patients. The simultaneous increase in
VEGF165 and Mac-1 gene expression within the plaque
suggests a link between elevated leptin receptor levels and
increased inflammation and stimulus for angiogenesis.
Abundant ObR antigen and increased macrophage density
could contribute to plaque instability and may eventually
translate into clinical symptoms. Large-scale simultaneous
genetic and clinical studies are warranted to further sub-
stantiate the potential linkage between leptin receptor,
enhanced atherogenesis, and plaque vulnerability in the
carotid artery and other vascular beds. Further investigation
of ObR in conjunction with imaging techniques may sup-
port the concept of the receptor as a novel local biomarker
for plaque and patient vulnerability.
We would like to acknowledge the contribution of Dr
Isaac Engelberg, for expert pathologic interpretations, and
Prof Raphael Adar, for critical review of the manuscript.
Also notable, Stephanie Minne and Sarah Henkel for excel-
lent technical support.
AUTHOR CONTRIBUTIONS
Conception and design: JS, KS
Analysis and interpretation: JS, AS, MS, MF, SK, KS
Data collection: JS, AS, KS
Writing the article: JS, KS
Critical revision of the article: JS, AS, MS, MF, SK, KS
Final approval of the article: JS, AS, MS, MF, SK, KS
Statistical analysis: AS, MS, MF, KS
Obtained funding: Not applicable
Overall responsibility: JS
REFERENCES
1. Carr S, Farb A, Pearce WH, Virmani R, Yao JS. Atherosclerotic plaque
rupture in symptomatic carotid artery stenosis. J Vasc Surg 1996;23:
755-65.
2. Golledge J, Greenhalgh RM, Davies AH. The symptomatic carotid.
Stroke 2000;31:774-81.
3. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons
from sudden coronary death: a comprehensive morphological classifi-
cation scheme for atherosclerotic lesions. Arterioscler ThrombVasc Biol
2000;20:1262-75.
4. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnera-
ble plaque. J Am Coll Cardiol 2006;47:C13-8.
5. McCarthy MJ, Loftus IM, Thompson MM, Lones L, London NJM,
Bell PRF, et al. Angiogenesis and the atherosclerotic carotid plaque: An
association between symptomatology and plaque morphology. J Vasc
Surg 1999;30:261-8.
6. Dunmore BJ, McCarthy MJ, Naylor AR, Brindle NPJ. Carotid plaque
instability and ischemic symptoms are linked to immaturity of microves-
sels within plaques. J Vasc Surg 2007;45:155-9.
7. MacDougald OA, Hwang CS, Fan H, Lane MD. Regulated expression
of the obese gene product (leptin) in white adipose tissue and 3T3-L1
adipocytes. Proc Natl Acad Sci U S A 1995;92:9034-7.
8. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006;189:
47-60.
9. Soderberg S, Ahren B, Jansson JH, JohnsonO,Hallmans G, Asplund K,
et al. Leptin is associated with increased risk of myocardial infarction.
J Intern Med 1999;246:409-18.
10. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A,
et al. Plasma leptin and the risk of cardiovascular disease in the West of
Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001;
104:3052-6.11. Shamsuzzaman ASM, Winnicki M, Wolk R, Svatikova A, Phillips BG,
Davison DE, et al. Independent association between plasma leptin and
C-reactive protein in healthy humans. Circulation 2004;109:2181-5.
12. Piatti P, Di Mario C, Monti LD, Fragasso G, Sgura F, Caumo A, et al.
Association of insulin resistance, hyperleptinemia, and impaired nitric
oxide release with in-stent restenosis in patients undergoing coronary
stenting. Circulation 2003;108:2074-81.
13. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL,
Wolfson SK Jr. Carotid-artery intima and media thickness as a risk
factor for myocardial infarction and stroke in older adults: Cardio-
vascular health study collaborative research group. N Engl J Med
1999;340:14-22.
14. CicconeM, Vettor R, Pannacciulli N,Minenna A, BellaciccoM, Rizzon
P, et al. Plasma leptin is independently associated with the intima-media
thickness of the common carotid artery. Int J Obes Relat Metab Disord
2001;25:805-10.
15. Zarkesh-Esfahani H, Pockley G, Metcalfe RA, Bidlinmaier M, Wu Z,
Ajami A, et al. High-dose leptin activates human leukocytes via receptor
expression on monocytes. J Immunol 2001;167:4593-9.
16. Kang SM, Kwon HM, Hong BK, Kim D, Kim IJ, Choi EY, et al.
Expression of leptin receptor (Ob-R) in human atherosclerotic lesions:
Potential role in intimal neovascularization. Yonsei Med J 2000;41:
68-75.
17. Schroeter MR, Schneiderman J, Schumann B, Glückermann R, Grim-
mas P, Buchwald AB, et al. Expression of the leptin receptor in different
types of vascular lesions. Histochem Cell Biol 2007;128:323-33.
18. North American Symptomatic Carotid Endarterectomy Trial Collabo-
rators. Beneficial effect of carotid endarterectomy in symptomatic pa-
tients with high-grade carotid stenosis. N Engl J Med 1991;325:
445-53.
19. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr,
et al. A definition of advanced types of atherosclerotic lesions and a
histological classification of atherosclerosis. A report from the Commit-
tee on Vascular Lesions of the Council on Arteriosclerosis, American
Heart Association. Circulation 1995;92:1355-74.
20. Hatsukami TS, Ferguson MS, Beach KW, Gordon D, Detmer P, Burns
I, et al. Carotid plaque morphology and clinical events. Stroke 1997;
28:95-100.
21. Bouloumie A, Drexler HC, Lafontan M, Busse R. Leptin, the product
of Ob gene, promotes angiogenesis. Circ Res 1998;83:1059-66.
22. Schäfer K, HalleM, Goeschen C, Dellas C, PynnM, Loskutoff DJ, et al.
Leptin promotes vascular remodeling and neointimal growth in mice.
Arterioscler Thromb Vasc Biol 2004;24:112-7.
23. Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, et al.
Potential role of leptin in angiogenesis: leptin induces endothelial cell
proliferation and expression of matrix metalloproteinases in vivo and in
vitro. Exp Mol Med 2001;33:95-102.
24. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN,
et al. Atherosclerotic plaque progression and vulnerability to rupture:
angiogenesis as a source of intraplaque hemorrhage. Arterioscler
Thromb Vasc Biol 2005;25:2054-61.
25. Lucema M, Zernecke A, de Nooijer R, de Jager SC, Bot I, van der Lans
C. Vascular endothelial growth factor-A induces plaque expansion in
ApoE knock-out mice by promoting de novo leukocyte recruitment.
Blood 2007;109:122-9.
26. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll
Cardiol 2003;41:15-22.
27. BassiounyHS, Davis H,MassawaN, Gewertz BL, Glagov S, Zarins CK.
Critical carotid stenoses: Morphological and chemical similarities be-
tween symptomatic and asymptomatic plaques. J Vasc Surg 1989;9:
202-2.
28. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery
plaque: current imaging methods and new perspectives. Stroke 2005;
36:2764-72.
29. Touzé E, Toussaint JF, Coste J, Schmitt E, Bonneville F, Vander-
marcq P, et al. HIgh-Resolution magnetic resonance Imaging in
atherosclerotic Stenosis of the Carotid artery (HIRISC) study group.
Reproducibility of high-resolution MRI for identification and quan-
tification of carotid atherosclerotic plaque components. Stroke
2007;38:1812-9.
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 5 Schneiderman et al 115530. Maseri A, Fuster V. Is there a vulnerable plaque? Circulation 2003;107:
2068-71.
31. Spagnoli LG, Mauriello A, Sangiorgi G, Fratoni S, Bonanno E,
Schwartz RS, et al. Extracranial thrombotically active carotid plaque as
a risk factor for ischemic stroke. JAMA 2004;292:1845-52.
32. Konstantinides S, Schäfer K, Koschnick S, Loskutoff DJ. Leptin depen-
dent platelet aggregation and arterial thrombosis suggests a mechanism
for atherosclerotic disease in obesity. J Clin Invest 2001;108:1533-40.
33. Bodary PF, Gu S, Shen Y, Hasty AH, Buckler JM, Eitzman DT.
Recombinant leptin promotes atherosclerosis and thrombosis in apoli-
poprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005;25:34. Taleb S, Herbin O, Ait-Oufella H, Verreth W, Gourdy P, Barateau
V, et al. Defective leptin/leptin receptor signaling improves regulatory
T cell immune response and protects mice from atherosclerosis. Arte-
rioscler Thromb Vasc Biol 2007;27:2691-8.
35. KaradumanM, Oktenli C, Musabak U, Sengul A, Yesilova Z, Cingoz F,
et al. Leptin, soluble interleukin-6 receptor, C-reactive protein and
soluble vascular cell adhesion molecule-1 levels in human coronary
atherosclerotic plaque. Br Soc Immunol, Clin Exp Immunol 2006;143:
452-7.e119-22. Submitted Mar 21, 2008; accepted Jun 23, 2008.
